Global healthcare is back in focus as inflation pressures and higher rates keep investors hunting for sectors where demand is less tied to the economic cycle. That puts high quality medical and drug developers, with solid finances and established operations, on many watchlists. This article highlights three leading healthcare stocks from a curated screener that filters for balance sheet strength and durable business models, helping you narrow a crowded field quickly.
The companies highlighted next are only a small sample. The wider screen surfaces 31 more healthcare stocks with balance sheet strength and long term business potential that are not covered in this article. To see the full picture, head straight to the Best Healthcare Stocks screener to identify, filter, and analyze the highest conviction ideas in the group.
Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics focuses on dermatology treatments, anchored by ZORYVE creams and foams, which ties it tightly to the Best Healthcare Stocks theme of biopharma drugs used directly in patient care. The business reports about $508 million in dermatology treatment revenue and has a market cap near $3.6 billion.
For investors hunting for healthcare stocks backed by marketed therapies rather than concepts on a slide deck, Arcutis Biotherapeutics offers a real world case study in how a dermatology drug can reshape a young biopharma, according to Coward_Nutlick, an investor in the Simply Wall St Community who recently set out their thesis.
"It is almost impossible to obtain a drug label from the FDA for pediatric use. This topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients."
What happens if one still largely underappreciated shift in prescribing patterns and treatment preferences moves faster than most investors currently expect?
That kind of shift is exactly what the full narrative for Arcutis Biotherapeutics unpacks, showing how an overlooked dermatology pivot could accelerate or stall the Arcutis Biotherapeutics story beyond ZORYVE.
Axogen (AXGN)
Axogen focuses tightly on peripheral nerve repair, which places it squarely in the Best Healthcare Stocks theme for specialized medical equipment and life sciences. The business generates about $266.9 million from nerve repair solutions and carries a market value close to $3.0b.
Axogen slots into this Best Healthcare Stocks group as the pure-play nerve repair specialist, with Avance and Axoguard implants turning complex injuries into a defined treatment path. According to the analyst consensus Narrative on Simply Wall St, the long-term commercial opportunity is closely tied to how regulators treat its lead biologic product.
"Upcoming FDA Biologics License Application (BLA) approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity and establish Avance as the only biologic with this indication, which should drive pricing power, limit biosimilar competition, and boost both gross margin and long-term earnings visibility."
One key consideration for investors is what might happen if a single assumption about future procedure volumes shifts and the nerve repair market absorbs these products more slowly than current expectations imply.
If that risk-reward balance interests you, the full narrative for Axogen shows how Axogen could accelerate or stall as procedure trends and regulator decisions interact.
Natera (NTRA)
Natera runs a broad molecular diagnostics business, with oncology and prenatal tests like Signatera, Latitude and Panorama directly plugged into frontline healthcare delivery. The group generates about US$2.9b from testing services and carries a market cap near US$45.2b.
The analyst consensus Narrative on Simply Wall St frames Natera as a key healthcare diagnostics player where oncology and women’s health testing are already embedded in day to day care decisions, with the real interest in how far that adoption curve can still run.
"Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera). This will likely boost top-line revenue."
The real swing factor is how one still unresolved pressure on future reimbursement shapes the path from high test volumes to lasting margin strength.
That reimbursement overhang is exactly what the full narrative for Natera unpacks, showing where accelerating test adoption could decouple Natera’s volumes from long term earnings power.
Seeking Alternatives Beyond These Healthcare Leaders
Fresh opportunities move quickly, and the most interesting ideas rarely stay under the radar for long. Scan what could be next before the crowd catches up and act now.
- Spot early momentum shifts in smaller companies that already have real earnings strength by running the 42 profitable AI stocks that aren't just burning cash while it is still flying below most investors’ screens.
- Track where cash rich balance sheets meet resilient business models using the curated list of solid balance sheet and fundamentals (23 results) before those stories are fully caught in broader market narratives.
- Target potential breakout moves in precious metals producers by checking the hand picked 33 elite gold producer stocks while sentiment is still dropping in and out of focus.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com